What Kind of Bioethics Council Do We Need?
By Marcy Darnovsky,
Science Progress
| 08. 17. 2009
Science Tells Us What We Can Do; Values Tell Us What We Should
Bioethics councils have come in many shapes and sizes, with different mandates, memberships, and outcomes. What kind of bioethics council would best serve the nation now? How can we move beyond the rancor and polarization-not to mention hyperbole and distortions on all sides-that in recent years have characterized so much of bioethics and the broader politics of science? There is no one answer, but a new council must incorporate viewpoints from Americans of all walks of life, maintain an appropriate distance from both scientific and commercial interests, and build on the experience of other nations.
President Obama's leadership on stem cell policies and politics begins to show a way forward. The President opened the remarks that accompanied his March executive order loosening restrictions on federal funding of embryonic stem cell research by invoking the work's great promise, and then immediately moved on to warn against overstating its potential. He noted the "difficult and delicate balance" between "sound science and moral values." He pledged that research supported by the federal government would be "both scientifically worthy and responsibly conducted" according to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...